MUC16 and neoplasm: To further analyse the tumor phenotype following administration of momelotinib and paclitaxel treatment in mice, the resected tumors of mice in Phase 1 were subjected to immunohistochemical analysis for the expression of cancer antigen 125 (CA125), proliferative marker Ki67, cluster of differentiation 31 (CD31), and CSC-like markers c-Kit and Oct3/4 (Figure 9).